Demo

Altris AI Press Kit: Key Executives’ Biographies, Current Press Release

 

BIOGRAPHIES OF KEY EXECUTIVES: MARIA ZNAMENSKA & ANDREY KUROPYATNYK

Maria Znamenska, MD, PhD, Associate Professor of Ophthalmology and
a Chief Medical Officer at Altris Inc.

  • Practicing Ophthalmologist with 16+ years of experience
  • Retina Imaging Expert with extensive knowledge of OCT and OCT-angiography
  • Ph.D. in Ophthalmology
  • MD in Healthcare Management
  • Owner of the practicing expert eye clinic in Kyiv, Ukraine
  • Running educational programs in Medical Retina, OCT, OCT-angiography, Glaucoma, Myopia, and Neuro-ophthalmology
  • Member of the European Society of Retina Specialists

Experience in OCT

  • Working with OCT since 2005 and OCT-angiography since 2016
  • Teaching OCT interpretation to Retina specialists since 2013
  • Leading a medical stream of R&D of the US health-tech company Altris Inc. since 2017
  • Her medical team launched Altris Education OCT and OCT-angiography training courses for ophthalmologists in Eastern Europe and the CIS region at the beginning of 2020

Altris team

Andrey Kuropyatnyk, MBA, CEO and Founder of Altris AI

  • Over 18 years of experience as a tech entrepreneur in business leadership, analysis, consulting, and IT systems development
  • Proven track record in the IT sector, specializing in process and project management
  • Skilled in leading innovation, driving organizational efficiency, and motivating high-performing teams
  • Extensive consulting background focused on process optimization and Agile implementation for software development teams

Education

  • The University of Chicago Booth School of Business Master of Business Administration (M.B.A.)
  • International Institute of Business, Ukrainian Program of Business Administration and Finance
  • Kyiv National University of Technology and Design Master’s degree, Quality, standardization and certification
  • Certifications in Enterprise Services Planning and Product Ownership

CURRENT PRESS RELEASE

AI-Powered OCT Analysis 

Altris AI is an artificial intelligence platform for OCT analysis used by more than 500 eye-care businesses worldwide. Unlike other solutions, which require a pre-existing assumption about a particular biomarker or a pathology, Altris AI identifies a wide range of retinal conditions (70+) without the need for targeted searches.

The goal of the Altris AI team is to make the Optical Coherence Tomography (OCT) analysis workflow more efficient and improve patient outcome as a result. This is achieved with the help of AI algorithms that sort out pathological OCT scans and analyze them for the presence of retina pathologies and biomarkers. 

First, the AI Severity detection module detects all non-pathological OCT scans. This means that an eye care specialist can only work with scans where retina pathologies and biomarkers are present. Which automatically means more time for patient communication.

Second, Altris AI analyzes pathological OCT scans on the presence/absence of 70+ retina pathologies and biomarkers. The list includes some prevalent pathologies and biomarkers, such as Geographic Atrophy, Diabetic Retionopathy, and various types of drusen, as well as rare biomarkers, such as Tapetoretinal Degeneration or  Macular Telangiectasia Type 2. More than that, the Progression tracking Module helps to see how pathologies are transforming over time quantitatively.

There is also a completely new module inside Altris AI that is worth mentioning: the Glaucoma Early Risk Assessment Module. It combines Ganglion Cell Complex (GCC) Analysis and Advanced Optic Disc (OD) Analysis. Optic Disc (OD) Analysis provides a broader picture of structural damage and allows detailed glaucoma assessment for more efficient treatment choices. This represents a transformative approach to glaucoma detection and management. OCT provides high-resolution imaging of retinal structures, allowing for precise measurement of optic disc and macula ganglion cell complex integrity.

Altris AI applies advanced machine learning algorithms to these datasets, detecting early glaucomatous changes with high sensitivity and specificity. This AI-powered platform highlights subtle structural abnormalities, and flags areas of concern. It assists in the detection of early stages of the disease, while also enabling longitudinal monitoring of disease progression. By combining OCT imaging with Altris AI, optometrists can enhance diagnostic precision, ensure earlier intervention, and optimize long-term visual outcomes for their patients.

“At Altris AI, we are thrilled to introduce a new way of working with OCT: faster, more informative, and with more control,” comments Maria Znamenska, Medical Director of Altris AI, MD, PhD in Ophthalmology. “Our team of retina experts and IT specialists has worked tirelessly to develop cutting-edge technologies that will set higher standards in the eye care industry and improve patient outcomes as a result.”

 

COMPANY FACT SHEET

 

TESTIMONIALS can be found here.

IMAGES  can be found here.